Get started

Financials · OPRX

OptimizeRx Corporation (OPRX) financials

For the twelve months ended Jun 30, 2026, OptimizeRx Corporation reported $98.65M of revenue and $4.60M of net income.

Revenue, TTM
$98.65M
Revenue growth, YoY
-5.8%
Net income, TTM
$4.60M
Net margin
4.7%
Free cash flow, TTM
$18.36M
EPS, diluted, TTM
$0.24
Cash
$24.10M
Total debt
$19.01M
P/E
35.86
P/S
1.67
Market cap
$165.0M
Annual revenue$109.43M
FY2016FY2025
Annual net income$5.13M
FY2016FY2025
Annual free cash flow$18.66M
FY2016FY2025

OPRX revenue and earnings growth

OPRX revenueQ2 2026$20.50M

Quarter YoY
-29.8%
QoQ
+3.3%
FY YoY
+18.8%
5Y CAGR
+20.4%
10Y CAGR
+31.2%

OPRX revenue was $20.50M in fiscal Q2 2026 (ended Jun 30, 2026), down 29.8% from a year earlier and up 3.3% from the prior quarter. For the full fiscal 2025 it was $109.43M, up 18.8% from fiscal 2024. Compound annual growth was +20.4% over 5 years and +31.2% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

OPRX net incomeQ2 2026-$703.0K

OPRX net income was -$703.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with $1.53M a year earlier. For the full fiscal 2025 it was $5.13M, compared with -$20.11M in fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.

OPRX EPSQ2 2026-$0.04

OPRX diluted EPS was -$0.04 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0.08 a year earlier. For the full fiscal 2025 it was $0.27, compared with -$1.10 in fiscal 2024.

OPRX free cash flowQ2 2026$8.58M

Quarter YoY
+88.4%
FY YoY
+290.6%
10Y CAGR
+43.2%

OPRX free cash flow was $8.58M in fiscal Q2 2026 (ended Jun 30, 2026), up 88.4% from a year earlier. For the full fiscal 2025 it was $18.66M, up 290.6% from fiscal 2024. Compound annual growth was +43.2% over 10 years. Fiscal 2025 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$109.43M$92.13M$71.52M$62.45M$61.29M$43.31M$24.60M$21.21M$12.13M$7.75M
Cost of revenue$35.83M$32.75M$28.62M$23.48M$25.65M$19.21M$9.16M$9.00M--
Gross profit$73.59M$59.38M$42.90M$38.97M$35.64M$24.11M$15.44M$12.21M$5.95M$4.34M
Research and development$0$0---$0$1.60M$0--
Selling, general and admin---$33.49M$27.70M-----
Operating income$11.69M-$13.71M-$26.40M-$12.29M$361.1K-$2.14M-$3.69M$180.1K-$2.13M-$1.58M
Interest expense$5.29M$6.16M$1.45M-------
Pre-tax income$6.95M-$19.39M-$25.16M-$11.44M$378.1K-$2.21M-$4.04M$226.3K-$2.10M-$1.54M
Income tax$1.82M$725.0K-$7.60M----$898.0K---
Net income$5.13M-$20.11M-$17.57M-$11.44M$378.1K-$2.21M-$3.14M$226.3K-$2.10M-$1.54M
EPS, basic$0.28-$1.10-$1.03-$0.64$0.02-$0.15-$0.23$0.02-$0.21-$0.05
EPS, diluted$0.27-$1.10-$1.03-$0.64$0.02-$0.15-$0.23$0.02-$0.21-$0.05
Diluted shares19.0M18.3M17.1M17.8M17.7M14.8M13.4M11.9M9.8M29.7M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$23.36M$13.38M$13.85M$18.21M$84.68M$10.52M$18.85M$8.91M$5.12M$7.03M
Short-term investments$0$0-$55.93M------
Receivables$37.75M$38.21M$36.25M$22.16M$24.80M$17.89M$7.42M$6.46M$3.43M$1.95M
Current assets$64.72M$53.97M$54.33M$98.58M$115.11M$32.86M$27.14M$15.73M$8.81M$10.18M
Goodwill$70.87M$70.87M$78.36M$22.67M$14.74M$14.74M$14.74M$3.68M--
Total assets$176.92M$171.17M$183.37M$134.65M$140.99M$60.33M$56.64M$25.05M$9.76M$11.48M
Current liabilities$21.26M$18.65M$17.88M$8.40M$9.37M$10.03M$6.11M$4.23M$3.54M$3.67M
Short-term debt$4.25M$2.00M$2.00M-------
Long-term debt$21.42M$30.82M$34.23M-------
Total debt$25.68M$32.82M$36.23M-------
Total liabilities$48.62M$54.17M$56.82M$8.54M$9.61M$10.35M$11.78M$6.60M$3.54M-
Shareholders' equity$128.29M$117.00M$126.55M$126.11M$131.38M$49.97M$44.86M$18.46M$6.22M$7.81M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$18.71M$4.89M-$7.24M$10.65M$726.0K-$6.31M-$1.66M$792.6K-$1.48M-$466.0K
Capital expenditures$58.0K$112.0K$87.0K$81.0K$100.3K$68.0K$87.7K$34.4K$42.2K$178.4K
Free cash flow$18.66M$4.78M-$7.33M$10.57M$625.7K-$6.38M-$1.75M$758.2K-$1.52M-$644.4K
Investing cash flow$68.0K-$450.0K-$25.34M-$58.18M-$486.0K-$124.7K-$10.58M-$5.69M-$42.2K-$349.5K
Financing cash flow-$8.80M-$4.91M$28.22M-$18.95M$73.92M-$1.90M$22.18M$8.69M-$390.0K-$357.4K
Share repurchases--$7.52M$20.02M----$390.0K$806.9K
Stock-based compensation$6.96M$11.47M$13.72M$15.75M$5.49M$3.17M$2.26M$2.52M$87.4K$175.2K
Depreciation and amortization$4.33M$4.33M$2.40M$2.02M$1.97M$2.08M$1.28M$316.5K$324.6K$235.3K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY18.8%28.8%14.5%1.9%41.5%76.1%16.0%74.9%56.5%7.4%
Gross margin67.3%64.5%60.0%62.4%58.1%55.7%62.8%57.6%49.1%56.0%
Operating margin10.7%-14.9%-36.9%-19.7%0.6%-4.9%-15.0%0.8%-17.6%-20.4%
Net margin4.7%-21.8%-24.6%-18.3%0.6%-5.1%-12.8%1.1%-17.3%-19.9%
Free cash flow margin17.0%5.2%-10.2%16.9%1.0%-14.7%-7.1%3.6%-12.6%-8.3%
Return on equity4.0%-17.2%-13.9%-9.1%0.3%-4.4%-7.0%1.2%-33.8%-19.7%
Return on assets2.9%-11.7%-9.6%-8.5%0.3%-3.7%-5.5%0.9%-21.5%-13.4%
Current ratio3.042.893.0411.7412.293.284.443.722.492.78
Debt to equity0.200.280.29-------

Source: XBRL data OptimizeRx Corporation files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

OPRX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
OPRX$98.65M-5.8%$4.60M4.7%$165.0M
V$45.90B+14.8%$23.50B51.2%$755.16B
MA$36.29B+15.3%$16.96B46.7%$568.62B
BABACN¥1.02T+2.7%CN¥103.59B10.1%$265.13B
ACN$74.18B+6.5%$8.37B11.3%$174.20B
UBER$56.53B+13.9%$3.46B6.1%$140.05B
PDDCN¥431.85B+9.7%CN¥97.84B22.7%$118.18B
DASH$17.06B+35.0%$1.06B6.2%$78.33B
MELI$38.52B+47.1%$1.89B4.9%$76.55B

OPRX FAQ

9 questions
  • What is OPRX revenue?
    OptimizeRx Corporation (OPRX) reported $98.65M of revenue for the twelve months ended Jun 30, 2026. That is down 5.8% from the year before. Revenue for fiscal 2025 was $109.43M.
  • Is OPRX profitable?
    Yes. OptimizeRx Corporation earned $4.60M in net income for the twelve months ended Jun 30, 2026, a net margin of 4.7%.
  • How much cash and debt does OPRX have?
    OptimizeRx Corporation reported $24.10M in cash and cash equivalents and $19.01M of debt on its most recent balance sheet in SEC filings.
  • How fast is OPRX revenue growing?
    OptimizeRx Corporation's revenue changed +18.8% in fiscal 2025, to $109.43M. Its compound annual growth rate was +20.4% over 5 years and +31.2% over 10 years.
  • What is OPRX gross margin?
    OptimizeRx Corporation's gross profit was $72.24M on $98.65M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 73.2%.
  • What is OPRX free cash flow?
    OptimizeRx Corporation generated $18.36M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of $18.43M less capital expenditures.
  • What is OPRX earnings per share?
    Diluted earnings per share were $0.24 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did OPRX last report financial results?
    The latest statements here come from OptimizeRx Corporation's 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this OPRX financial data come from?
    Quantisnow builds these statements from the structured XBRL data OptimizeRx Corporation files with the SEC. It is provided for information only and is not investment advice.